GBA mutations increase risk for Lewy body disease with and without Alzheimer disease pathology

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Neurology

• Publication date

  2012-11-06

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1212/WNL.0b013e3182735e9aPMID 23035075PMCID PMC3484986
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• [Epidemiology of Parkinson's disease].

  2013cited by this paper
• Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease

  2011cited by this paper
• Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

  2011cited by this paper
• Glucocerebrosidase mutations in diffuse Lewy body disease.

  2011cited by this paper
• Acid β‐glucosidase mutants linked to gaucher disease, parkinson disease, and lewy body dementia alter α‐synuclein processing

  2011cited by this paper
• Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies.

  2011cited by this paper
• Association between male gender and cortical Lewy body pathology in large autopsy series

  2010cited by this paper
• Mutations for Gaucher disease confer high susceptibility to Parkinson disease.

  2009cited by this paper
• Association of glucocerebrosidase mutations with dementia with lewy bodies.

  2009cited by this paper
• Glucosidase-beta variations and Lewy body disorders.

  2009cited by this paper
• The neuropathology of probable Alzheimer disease and mild cognitive impairment

  2009cited by this paper
• Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease.

  2009cited by this paper
• Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria.

  2009cited by this paper
• Glucocerebrosidase gene mutations: a risk factor for Lewy body disorders.

  2008cited by this paper
• Empiric refinement of the pathologic assessment of Lewy-related pathology in the dementia patient.

  2008cited by this paper
• Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA)

  2008cited by this paper
• Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset

  2008cited by this paper
• Glucocerebrosidase mutations are an important risk factor for Lewy body disorders

  2006cited by this paper
• Epidemiology of Parkinson's disease.

  2006cited by this paper
• Diagnosis and management of dementia with Lewy bodies

  2005cited by this paper
• Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium

  2005cited by this paper
• Hematologically important mutations: Gaucher disease.

  2005cited by this paper
• Hematologically important mutations

  2005cited by this paper
• Neuropathology provides clues to the pathophysiology of Gaucher disease.

  2004cited by this paper
• Neuropathological stageing of Alzheimer-related changes

  2004cited by this paper
• Dementia and Alzheimer disease incidence: a prospective cohort study.

  2002cited by this paper
• Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases

  2002cited by this paper
• The Cognitive Abilities Screening Instrument (CASI): A Practical Test for Cross-Cultural Epidemiological Studies of Dementia

  1994cited by this paper
• The Consortium to Establish a Registry for Alzheimer's Disease (CERAD)

  1991cited by this paper
• University of Washington Alzheimer’s Disease Patient Registry (ADPR): 1987–8

  1990cited by this paper
• Clinical diagnosis of Alzheimer's disease

  1984cited by this paper

• Classification and Genotype–Phenotype Relationships of GBA1 Variants: MDSGene Systematic Review

  2025cites this paper
• Neuropathology of Lewy body dementia: Lewy-related pathology, α-synuclein oligomers, and comorbid pathologies

  2025cites this paper
• Synaptic vesicle endocytosis deficits underlie cognitive dysfunction in mouse models of GBA-linked Parkinson’s disease and dementia with Lewy bodies

  2025cites this paper
• Commander complex regulates lysosomal function and is implicated in Parkinson's disease risk.

  2025cites this paper
• A novel allosteric GCase modulator prevents Tau accumulation in GBA1WT and GBA1L444P/L444P cellular models

  2025cites this paper
• Severe Cognitive Decline in Long-term Care Is Related to Gut Microbiome Production of Metabolites Involved in Neurotransmission, Immunomodulation, and Autophagy

  2025cites this paper
• Dementia With Lewy Bodies.

  2025cites this paper
• Where do PDD and DLB SYNdromes fit in neuronal alpha-SYNuclein biological frameworks?

  2025cites this paper
• Targeted degradation of α-synuclein prevents PFF-induced aggregation

  2025cites this paper
• Pharmacological GCase Activity Enhancement Inhibits Tau Accumulation

  2024cites this paper
• HSPB6: A lipid-dependent molecular chaperone inhibits α-synuclein aggregation

  2024cites this paper
• GBA-AAV mitigates sleep disruptions and motor deficits in mice with REM sleep behavior disorder

  2024cites this paper
• Synaptic vesicle endocytosis deficits underlie GBA-linked cognitive dysfunction in Parkinson’s disease and Dementia with Lewy bodies

  2024cites this paper
• Synaptic vesicle endocytosis deficits underlie GBA-linked cognitive dysfunction in Parkinson’s disease and Dementia with Lewy bodies

  2024cites this paper
• Family History in Parkinson's Disease: A National Cross‐Sectional Study

  2024cites this paper
• The Body, the Brain, the Environment, and Parkinson’s Disease

  2024cites this paper
• Effect of GBA1 Mutations and APOE Polymorphisms on Survival and Progression Among Ashkenazi Jews with Dementia with Lewy Bodies

  2024cites this paper
• Autopsy-Proven "Pure" Parkinson's Disease with Rapidly Progressive Dementia and Cognitive Fluctuations in a Patient with GBA Mutation.

  2024cites this paper
• Dementia with Lewy Bodies: Genomics, Transcriptomics, and Its Future with Data Science

  2024cites this paper
• Genetic associations with dementia‐related proteinopathy: Application of item response theory

  2024cites this paper
• Role of GBA variants in Lewy body disease neuropathology

  2024cites this paper
• Tau accumulation in degradative organelles is associated to lysosomal stress

  2023cites this paper
• A Preliminary Comparison of the Methylome and Transcriptome from the Prefrontal Cortex Across Alzheimer’s Disease and Lewy Body Dementia

  2023cites this paper
• Decoding Neurodegeneration: A Comprehensive Review of Molecular Mechanisms, Genetic Influences, and Therapeutic Innovations

  2023cites this paper
• Mechanisms of Glucocerebrosidase Dysfunction in Parkinson's Disease.

  2023cites this paper
• Sex differences in dementia with Lewy bodies: Focused review of available evidence and future directions.

  2023cites this paper
• Lysosomal polygenic risk is associated with the severity of neuropathology in Lewy body disease

  2023cites this paper
• Exploring the link between GBA1 mutations and Dementia with Lewy bodies, A Mini-Review.

  2022cites this paper
• Frequency of Parkinson’s Disease Genes and Role of PARK2 in Amyotrophic Lateral Sclerosis: An NGS Study

  2022influential citation
• Mutant glucocerebrosidase impairs α-synuclein degradation by blockade of chaperone-mediated autophagy

  2022cites this paper
• Neuropathological substrates of cognition in Parkinson's disease.

  2022cites this paper
• Parkinson Disease and Subthalamic Nucleus Deep Brain Stimulation: Cognitive Effects in GBA Mutation Carriers

  2022cites this paper
• Clinical Manifestations and Molecular Backgrounds of Parkinson's Disease Regarding Genes Identified From Familial and Population Studies

  2022cites this paper
• Cognition as a mediator for gait and balance impairments in GBA-related Parkinson’s disease

  2022cites this paper
• Should we rethink neurodegeneration?

  2022cites this paper
• Differences in Sex‐Specific Frequency of Glucocerebrosidase Variant Carriers and Familial Parkinsonism

  2022cites this paper
• Identification of GBA mutations among Neurodegenerative disease Patients from eastern India.

  2021cites this paper
• Gut Microbiome Regulation of Autophagic Flux and Neurodegenerative Disease Risks

  2021cites this paper
• Delft University of Technology Genetics Contributes to Concomitant Pathology and Clinical Presentation in Dementia with Lewy Bodies

  2021cites this paper
• Lewy Body Dementias: Controversies and Drug Development

  2021cites this paper
• Bioinformatics analysis and identification of genes and molecular pathways involved in Parkinson’s disease in patients with mutations in the glucocerebrosidase gene

  2021cites this paper
• Alpha-Synuclein and Cognitive Decline in Parkinson Disease

  2021cites this paper
• Genetic Architecture and Molecular, Imaging and Prodromic Markers in Dementia with Lewy Bodies: State of the Art, Opportunities and Challenges

  2021cites this paper
• New therapeutic approaches to Parkinson's disease targeting GBA, LRRK2 and Parkin.

  2021cites this paper
• Glucocerebrosidase Gene Therapy Induces Alpha-Synuclein Clearance and Neuroprotection of Midbrain Dopaminergic Neurons in Mice and Macaques

  2021cites this paper
• Glucocerebrosidase mutations: A paradigm for neurodegeneration pathways.

  2021cites this paper
• Mutations in GBA, SNCA, and VPS35 are not associated with Alzheimer’s disease in a Chinese population: a case-control study

  2021cites this paper
• Genetics Contributes to Concomitant Pathology and Clinical Presentation in Dementia with Lewy Bodies

  2021cites this paper
• Genetic Defects and Pro-inflammatory Cytokines in Parkinson's Disease

  2021cites this paper
• Clinical implications for dopaminergic and functional neuroimage research in cognitive symptoms of Parkinson’s disease

  2021cites this paper
• Parkinson's disease: Genetic-driven therapeutic approaches

  2021cites this paper
• Glucocerebrosidase reduces the spread of protein aggregation in a Drosophila melanogaster model of neurodegeneration by regulating proteins trafficked by extracellular vesicles.

  2021cites this paper
• The Effect of GBA Mutations and APOE Polymorphisms on Dementia with Lewy Bodies in Ashkenazi Jews

  2021cites this paper
• Pathological Influences on Clinical Heterogeneity in Lewy Body Diseases

  2020cites this paper
• GBA Gene

  2020cites this paper
• Title: Systematic review of genetic association studies in people with Lewy body dementia Short running title: Genetics of Lewy body dementia

  2020cites this paper
• Dementia With Lewy Bodies

  2020cites this paper
• Systematic review of genetic association studies in people with Lewy body dementia

  2020cites this paper
• Epigenetic Regulation in the pathophysiology of Lewy Body Dementia.

  2020cites this paper
• Glucocerebrosidase reduces the spread of protein aggregation in a Drosophila melanogaster model of neurodegeneration by regulating proteins trafficked by extracellular vesicles

  2020cites this paper
• Genetic architecture of common non-Alzheimer’s disease dementias

  2020cites this paper
• GBA variation and susceptibility to multiple system atrophy.

  2020cites this paper
• Glucocerebrosidase mutations and neuropsychiatric phenotypes in Parkinson’s disease and dementia: review and meta-analyses. Running title: Review of GBA and neuropsychiatric phenotypes Authors:

  2020cites this paper
• Challenges and opportunities for improving the landscape for Lewy body dementia clinical trials

  2020cites this paper
• Distinguishing Dementia With Lewy Bodies From Alzheimer's Disease: What is the Influence of the GBA Genotype in Ashkenazi Jews?

  2019cites this paper
• Dysregulated Lipid Metabolism and Its Role in α-Synucleinopathy in Parkinson’s Disease

  2019cites this paper
• Dementia with Lewy Bodies

  2019cites this paper
• Role of β-glucosidase 2 in aberrant glycosphingolipid metabolism: model of glucocerebrosidase deficiency in zebrafish[S]

  2019cites this paper
• GBA1-associated parkinsonism: new insights and therapeutic opportunities.

  2019cites this paper
• Lipid and immune abnormalities causing age-dependent neurodegeneration and Parkinson’s disease

  2019cites this paper
• The role of dopamine in the pathogenesis of GBA1-linked Parkinson's disease.

  2019cites this paper
• Dementia associated with disorders of the basal ganglia

  2019cites this paper
• Genome sequencing for early-onset dementia: high diagnostic yield and frequent observation of multiple contributory alleles

  2019cites this paper
• Impaired β-glucocerebrosidase activity and processing in frontotemporal dementia due to progranulin mutations

  2019cites this paper
• Insights into GBA Parkinson's disease pathology and therapy with induced pluripotent stem cell model systems.

  2019cites this paper
• Functionalized Cyclophellitols Are Selective Glucocerebrosidase Inhibitors and Induce a Bona Fide Neuropathic Gaucher Model in Zebrafish

  2019cites this paper
• The role of monogenic genes in idiopathic Parkinson's disease.

  2019cites this paper
• Probable role of Arthrospira platensis in neurodegenerative disorder as neuroprotective agent

  2019influential citation
• Genome sequencing for early-onset or atypical dementia: high diagnostic yield and frequent observation of multiple contributory alleles

  2019cites this paper
• In vivo inactivation of glycosidases by conduritol B epoxide and cyclophellitol as revealed by activity‐based protein profiling

  2019cites this paper
• Glucocerebrosidase mutations and synucleinopathies: Toward a model of precision medicine

  2019cites this paper
• Risk stratification and targeted neuroprotection in Parkinson disease utilising the glucocerebrosidase pathway

  2018cites this paper
• Cognition among individuals along a spectrum of increased risk for Parkinson’s disease

  2018cites this paper
• Candidate‐based screening via gene modulation in human neurons and astrocytes implicates FERMT2 in A&bgr; and TAU proteostasis

  2018cites this paper
• The Contribution of Tau, Amyloid-Beta and Alpha-Synuclein Pathology to Dementia in Lewy Body Disorders

  2018cites this paper
• Dementia with Lewy bodies — from scientific knowledge to clinical insights

  2018cites this paper
• Genetics of Parkinson disease.

  2018cites this paper
• The Genetics of Dementia with Lewy Bodies: Current Understanding and Future Directions

  2018cites this paper
• Features of GBA-associated Parkinson’s disease at presentation in the UK Tracking Parkinson’s study

  2018cites this paper
• Glucocerebrosidase mutations and parkinsonism: how much does the mutation matter?

  2018cites this paper
• Augmented frontal cortex diacylglycerol levels in Parkinson’s disease and Lewy Body Disease

  2018cites this paper
• Modulation of &bgr;-glucocerebrosidase increases &agr;-synuclein secretion and exosome release in mouse models of Parkinson’s disease

  2018cites this paper
• Glucocerebrosidase mutations and neuropsychiatric phenotypes in Parkinson's disease and Lewy body dementias: Review and meta‐analyses

  2018cites this paper
• Religious Orders Study and Rush Memory and Aging Project

  2018cites this paper
• GBA-Associated Parkinson’s Disease and Other Synucleinopathies

  2018cites this paper
• Recent advances in the diagnosis and management of Gaucher disease

  2018cites this paper
• Frequency of GBA Variants in Autopsy‐proven Multiple System Atrophy

  2017cites this paper
• New Therapeutic Strategies for Lewy Body Dementias

  2017cites this paper
• Molecular Genetics of Neurodegenerative Dementias.

  2017influential citation
• Lewy body dementia

  2017cites this paper